-
Mashup Score: 61Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions - 8 day(s) ago
AbstractArtificial intelligence (AI) in oncology is advancing beyond algorithm development to integration into clinical practice. This review describes the current state of the field, with a specific focus on clinical integration. AI applications are structured according to cancer type and clinical domain, focusing on the four most common cancers and tasks of detection, diagnosis, and treatment. These applications encompass various data modalities, including imaging, genomics, and medical records. We conclude with a summary of existing challenges, evolving solutions, and potential future directions for the field.Significance:. AI is increasingly being applied to all aspects of oncology, where several applications are maturing beyond research and development to direct clinical integration. This review summarizes the current state of the field through the lens of clinical translation along the clinical care continuum. Emerging areas are also highlighted, along with common challenges, evo
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Are we entering a new era of cancer treatments? - 2 month(s) ago
Cancer patient survival rates are better than ever, but many cancers remain tough to treat. The current wave of innovations in science and technology could provide new answers. Learn why scientists are focusing on the unique biology of each patient and how Amgen is part of the movement. (Partner Content)
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 105Cancer Today - 3 month(s) ago
CANCER TODAY enables a comprehensive assessment of the cancer burden worldwide in 2022, based on the GLOBOCAN estimates of incidence, mortality and prevalence for year 2022 in 185 countries or territories for 36 cancer types by sex and age group.
Source: gco.iarc.frCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Next generation radiotheranostics promoting precision medicine - 5 month(s) ago
Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-DOTATATE for neuroendocrine tumors, and 177Lu-PSMA (prostate-specific membrane antigen) for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.
Source: www.annalsofoncology.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 109Antibody–drug conjugates: in search of partners of choice - 7 month(s) ago
Antibody–drug conjugates (ADCs) have become a credentialled class of anticancer drugs for both solid and hematological malignancies, with regulatory a…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results - 7 month(s) ago
Nature Medicine – In the first stage of the BR.36 adaptive trial in patients with non-small cell lung cancer receiving anti-PD1 immunnotherapy, the primary endpoint of concordance between…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3The cancer-immunity cycle: Indication, genotype, and immunotype - 7 month(s) ago
The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterat…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5
AbstractSmall-molecule drugs have enabled the practice of precision oncology for genetically defined patient populations since the first approval of imatinib in 2001. Scientific and technology advances over this 20-year period have driven the evolution of cancer biology, medicinal chemistry, and data science. Collectively, these advances provide tools to more consistently design best-in-class small-molecule drugs against known, previously undruggable, and novel cancer targets. The integration of these tools and their customization in the hands of skilled drug hunters will be necessary to enable the discovery of transformational therapies for patients across a wider spectrum of cancers.Significance:. Target-centric small-molecule drug discovery necessitates the consideration of multiple approaches to identify chemical matter that can be optimized into drug candidates. To do this successfully and consistently, drug hunters require a comprehensive toolbox to avoid following the “law of in
Source: aacrjournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 25Trends in the approval of cancer therapies by the FDA in the twenty-first century - Nature Reviews Drug Discovery - 10 month(s) ago
Cancer therapy has changed substantially since the beginning of the century, with advances including kinase inhibitors and immunotherapies resulting in substantial improvements in treatment outcomes. This Review summarizes trends in the approval of oncology therapeutic products by the FDA since 2000 and discusses the implications for the future of anticancer drug development.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Trends in the approval of cancer therapies by the FDA in the twenty-first century - Nature Reviews Drug Discovery - 10 month(s) ago
Cancer therapy has changed substantially since the beginning of the century, with advances including kinase inhibitors and immunotherapies resulting in substantial improvements in treatment outcomes. This Review summarizes trends in the approval of oncology therapeutic products by the FDA since 2000 and discusses the implications for the future of anticancer drug development.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
The potential role of AI in clinical practice for oncology is anchored around improving detection, diagnosis, and treatment. https://t.co/xhODvLFAOW https://t.co/9hSkrVtncE